What's worth trying—and why

Peptides, biomarkers, and real experiments. The studies, numbers, and firsthand results behind your next health decision.

Kisspeptin: The Brain Hormone Behind a 56% Arousal Result

Oct 23, 2026

•

5 min read

Kisspeptin: The Brain Hormone Behind a 56% Arousal Result

Men with low sexual desire watched a video during a controlled hormone infusion. Their physical response grew. The details explain what that result could mean for treatment.

Exenatide: The Diabetes Drug That Began in Lizard Venom

Oct 21, 2026

•

5 min read

Exenatide: The Diabetes Drug That Began in Lizard Venom

The human gut already makes a hormone that helps control blood sugar. Its short life created a drug-development problem that a desert lizard helped solve.

PT-141: The Tanning Experiment That Led to a Desire Drug

Oct 19, 2026

•

5 min read

PT-141: The Tanning Experiment That Led to a Desire Drug

An unexpected erection redirected peptide research. The eventual medicine was tested for a different problem: low sexual desire that causes distress.

Retatrutide: The Trial Behind 28% Weight Loss

Oct 16, 2026

•

7 min read

Retatrutide: The Trial Behind 28% Weight Loss

A peptide that activates three hormone receptors has reached Phase 3 results. Here is how to read its weight-loss headline, the liver-fat findings, and the comparison still underway.

Ziconotide: The Snail Venom Peptide That Became a Pain Medicine

Oct 14, 2026

•

5 min read

Ziconotide: The Snail Venom Peptide That Became a Pain Medicine

A molecule from a fish-hunting snail reached human trials. Its path to approval explains why a powerful pain signal blocker still needs specialist care.

What's worth trying—and why

Kisspeptin: The Brain Hormone Behind a 56% Arousal Result

Exenatide: The Diabetes Drug That Began in Lizard Venom

PT-141: The Tanning Experiment That Led to a Desire Drug

Retatrutide: The Trial Behind 28% Weight Loss

Ziconotide: The Snail Venom Peptide That Became a Pain Medicine

First Dose